Detailed Narrative
Q4 Performance and End Market Trends
Danaher delivered a strong fourth quarter for FY25, exceeding margin, earnings, and cash flow expectations across its portfolio. End market trends were largely consistent with the first three quarters of the year, characterized by robust global monoclonal antibody production and a modestly more favorable capital spending environment within the pharmaceutical sector. The company also observed a continued recovery in pharma R&D spending, while academic and government demand remained muted but stable sequentially. Clinical and applied end markets continued to perform well, contributing to the overall positive finish to the year.
Innovation Driving Growth
The company highlighted an accelerated cadence of new product introductions throughout 2025, which significantly contributed to financial results, including approximately 25% year-over-year growth in new product revenue. Noteworthy launches included Cytiva's new 500- and 2,000-liter Xcellerex X-platform bioreactor formats and two new protein A resins (MabSelect SuRe 70 and MabSelect PrismA X). In Life Sciences, SCIEX introduced the ZenoTOF 8600 mass spectrometer, and Beckman Coulter Life Sciences expanded its flow cytometry portfolio with the mosaic Spectral Detection Module. Diagnostics saw Beckman Coulter Diagnostics expand its DxI 9000 assay menu, and Cepheid received FDA clearance for its Xpert GI Panel, leveraging multiplex PCR technology.
Bioprocessing Outlook and Long-Term Drivers
The Biotechnology segment's bioprocessing core revenue grew high single-digits in Q4, driven by strong consumables demand and a return to equipment revenue growth. For FY26, Danaher anticipates high single-digit core revenue growth in bioprocessing, primarily led by consumables, with equipment revenue expected to be approximately flat. Management expressed strong confidence in the long-term growth of the bioprocessing market, citing over a decade of double-digit annual growth in underlying biologic demand, robust FDA approvals for biologic medicines in 2025, and projections that biologics will constitute over two-thirds of the top 100 drugs by 2030.
Life Sciences and Diagnostics Segment Dynamics
Life Sciences core revenue increased 0.5% in Q4, with instrument businesses remaining flat and consumables experiencing a decline due to reduced demand for plasmids and mRNA from specific large customers, alongside funding pressures in early-stage biotech and academic research. Abcam showed encouraging sequential improvement, achieving three months of growth driven by recombinant proteins and the pharma segment. The Diagnostics segment recorded 2% core revenue growth, with clinical diagnostics growing mid-single digits, particularly strong outside China. Cepheid's core non-respiratory test menu grew low double-digits, notably in sexual health and hospital-acquired infection assays, reflecting successful growth strategies and new menu additions.
M&A Environment and Capital Allocation
Management indicated a more constructive M&A environment, observing favorable valuation trends and moderated interest rates. Danaher's robust cash flow generation and strong balance sheet position the company to pursue strategic acquisition opportunities. The company maintains a disciplined approach, focusing on end markets with long-term tailwinds and attractive assets that offer defensible value creation. Danaher believes it is in the early stages of a long-term investment cycle, particularly in bioprocessing, driven by the necessity to meet existing demand and the ongoing trend of U.S. reshoring, which is expected to provide incremental upside.